Stock Forecast

  Dyne Therapeutics, Inc. ( DYN) Stock. Should you Buy or Sell?    $ 14.91

0.02 (0.13 %)



Dyne Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol DYN
Price $14.91
Beta 1.604
Volume Avg. $232.5 thousand
Market Cap $771.82 M
52 Week Range $4.3 - $17.89


Dyne Therapeutics, Inc. opened the day at $14.91 which is +'0.13 % on yesterday's close. Dyne Therapeutics, Inc. has a 52 week high of $17.89 and 52 week low of $4.3, which is a difference of $13.59. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $771.82 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Dyne Therapeutics, Inc. for $771.82 M, it would take 15 years to get your money back. Dyne Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Dyne Therapeutics, Inc. Stock Forecast - Is Dyne Therapeutics, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -4.228
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Dyne Therapeutics, Inc.


Price Book Value Ratio 2.684 Price To Book Ratio 2.684
Price To Sales Ratio 0.000 Price Earnings Ratio -4.228


How liquid is Dyne Therapeutics, Inc.


Current Ratio 11.628
Quick Ratio 11.390


Debt


Debt Ratio 0.156 Debt Equity Ratio 0.185
Long Term Debt To Capitalization 0.087 Total Debt To Capitalization 0.103



Latest news about Dyne Therapeutics, Inc.


Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY on Monday, September 12, 2022 at 2:15 p.m. ET.

Date : 06/09/2022

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"

Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of $17. "We believe that Avidity and Dyne are an.

Date : 20/07/2022

What's Going On With Dyne Therapeutics Shares Today?

Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duchenne muscular dystrophy. Dyne says the company plans to evaluate DYNE-251 in a global,.

Date : 05/07/2022

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 9, 2022 at 3:00 p.m. ET.

Date : 03/06/2022

Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday

A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.

Date : 18/01/2022





About Dyne Therapeutics, Inc.


CEO : None
Sector : Healthcare
Industry : Biotechnology

Website : https://www.dyne-tx.com

Exchange : NASDAQ Global Select

Description :

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..


My Newsletter

Sign Up For Updates & Newsletters